Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Paul Rosenberg

Psychiatry Baltimore, MD Medical Doctor

NPI 1942238563 CMS profile 269608

600 N Wolfe St, Baltimore, MD 21287

Open in the dashboard

General payments

$66,199

26 records reported · program years 2020–2025

Research payments

$810

Paid to them · 2 records reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,831,562 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Paul Rosenberg of Baltimore, MD is reported in the CMS Open Payments database as having received $66,199 across 26 general payments and $810 in research payments paid to them. Separately, studies naming them as principal investigator received $1,831,562 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,771 4
2024 General $15,135 4
2023 General $16,708 6
2022 General $12,285 8
2022 Research $540 1
2021 General $3,000 2
2020 General $9,300 2
2020 Research $270 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Rosenberg
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Paul Rosenberg were reported at $9,771. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Paul Rosenberg Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $9,300 $119 $36–$372 $114
2021 $3,000 $143 $43–$576 $132
2022 $12,285 $153 $50–$590 $149
2023 $16,708 $170 $56–$651 $160
2024 $15,135 $179 $57–$673 $164
2025 $9,771 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $22,488 13 payments
  2. Eli Lilly and Company $15,135 4 payments
  3. ACADIA Pharmaceuticals Inc $9,300 2 payments
  4. H. Lundbeck A S $6,746 5 payments
  5. Biogen, Inc. $6,375 1 payment
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $6,156 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $57,309 12 payments
  2. Honoraria $5,400 1 payment
  3. Travel and Lodging $2,685 9 payments
  4. Food and Beverage $806 4 payments
Products named General payments · program years 2020–2025
  1. REXULTI $6,746 5 payments
  2. NUPLAZID $5,700 1 payment
  3. DISEASE EDUCATION $3,600 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2020–2025
  1. Eli Lilly and Company $810 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

749

Median for Psychiatry: 574

Drug cost

$27,550

Median for Psychiatry: $27,624

Branded share of claims

13.8%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Galantamine Er Galantamine Hbr Brand 89 $8,458
Rivastigmine Generic 27 $6,831
Memantine Hcl Generic 94 $3,784
Donepezil Hcl Generic 155 $2,543
Escitalopram Oxalate Generic 82 $1,184
Mirtazapine Generic 36 $686
Divalproex Sodium Generic 15 $669
Olanzapine Generic 31 $668
Quetiapine Fumarate Generic 21 $544
Duloxetine Hcl Generic 19 $539

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$30,185

Medicare's payments for the services billed

Medicare patients

213

Average age 76

Services billed

373

110 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Alzheimer's or dementia 64%
Depression 45%
Arthritis 43%
Ischemic heart disease 29%
Diabetes 27%
Chronic kidney disease 23%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record